Showing 1911-1920 of 3223 results for "".
- Alcon Partners with Football Player Cooper Kupp to Promote Pataday for Eye Allergieshttps://modernod.com/news/alcon-partners-with-football-player-cooper-kupp-to-promote-pataday-for-eye-allergies/2480895/Alcon announced a partnership with Cooper Kupp, professional football wide receiver, to share his experience with eye allergies and help other eye allergy sufferers find relief with Pataday Once Daily Relief Extra Strength. 
- Alcon to Acquire Eysuvis and Inveltys from Kala Pharmaceuticalshttps://modernod.com/news/kala-pharmaceuticals-to-sell-eysuvis-and-inveltys-to-alcon/2480878/Alcon will significantly bolster its pharmaceutical offerings after reaching an agreement to acquire Kala Pharmaceuticals' commercial portfolio, which includes dry eye drug Eysuvis (loteprednol etabonate suspension 0.25%), and Inveltys (loteprednol etabonate
- Allotex Announces Eye Bank Executive Corrina Patzer Joining Board of Directorshttps://modernod.com/news/allotex-announces-eye-bank-executive-joining-board-of-directors/2480864/Allotex has announced that Corrina Patzer has been appointed to the company’s Board of Directors. "We are excited and honored to welcome Corrina as a new independent director to the Allotex BOD,” said David Muller, CEO of Allotex, “Corrina&rsq
- Alcon Celebrates 75th Anniversaryhttps://modernod.com/news/alcon-celebrates-75-years-of-eye-care-innovation/2480862/Alcon marked the company’s 75th anniversary this week with its "Brilliant History. Brilliant Future." celebration. On May 16, 1947, Alcon Laboratories Inc. was incorporated and began manufacturing specialty pharmaceutical products in Fort Worth, Texas. To
- Aldeyra Therapeutics to Present at MOD Live! 2022 Meetinghttps://modernod.com/news/aldeyra-therapeutics-to-present-at-mod-live-2022-meeting/2480843/Aldeyra Therapeutics announced that Kelly Mizer, Aldeyra’s Vice President, Commercial Strategy and Operations, will present at the MOD Live! 2022 meeting, which will take place in Nashville, Tennessee, May 5–7, 2022. MOD Live! 2022 is an interactive educational program
- Allergan to Present New Data from its Portfolio of Eye Care Treatments at ARVOhttps://modernod.com/news/allergan-to-present-new-data-from-its-portfolio-of-eye-care-treatments-at-arvo/2480817/Allergan announced that it will present new data on Vuity (pilocarpine HCl ophthalmic solution) 1.25%, the first and only FDA-approved eye drop for the treatment of presbyopia (age-related blurry near vision) in adults, and Durysta (bimatoprost
- Recent Alimera Data Featured in Scientific Programming at ARVOhttps://modernod.com/news/recent-alimera-data-featured-in-scientific-programming-at-arvo/2480813/Alimera Sciences announced today that Iluvien will be highlighted in various scientific abstracts at the annual Association for Research in Vision and Ophthalmology (ARVO) conference being held in Denver, Colorado from May 1-4 and virtually May 11-12, 2022.
- Allegro Ophthalmics Announces New Scientific Data to Be Presented During the 2022 ARVO Annual Meetinghttps://modernod.com/news/allegro-ophthalmics-announces-new-scientific-data-to-be-presented-during-the-2022-arvo-annual-meeting/2480806/Allegro Ophthalmics announced that two scientific posters involving risuteganib, the company’s lead investigational compound in retina, will be presented during the 2022 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. ARVO 2022 will be held May 1-4, 2022 in
- Alcon Announces Scientific Program at ASCRS 2022https://modernod.com/news/alcon-announces-scientific-program-at-ascrs-2022/2480782/Alcon will once again have a significant scientific presence at the American Society of Cataract and Refractive Surgery (ASCRS) 2022 annual meeting, taking place April 22-26 in Washington, DC. Approximately 150 abstracts feature Alcon’s leading ophthalmic products and equipment—with m
- Allergan to Present New Data from its Eye Care Portfolio at ASCRS 2022https://modernod.com/news/allergan-to-present-new-data-from-its-eye-care-portfolio-at-ascrs-2022/2480778/Allergan announced that it will present new data from its eye care portfolio at the 2022 ASCRS annual meeting being held April 22–26 in Washington, DC. Presentations will include new data on Vuity (pilocarpine HCl ophthalmic solution) 1.25%, the first and only